What is Liquidia?
Headquartered in Research Triangle Park, North Carolina, Liquidia Technologies, Inc. operates as a specialized biopharmaceutical firm focused on the development and commercialization of novel therapeutic products. The company's core competitive advantage lies in its proprietary PRINT technology, a sophisticated particle engineering platform that enables the precise production of uniform drug particles. This technical capability is designed to enhance the safety, efficacy, and overall performance of a diverse range of medical therapies. Currently, the firm is prioritizing the advancement of two primary product candidates: LIQ861, targeted at pulmonary arterial hypertension (PAH), and LIQ865, aimed at the management of local post-operative pain. Through these initiatives, Liquidia maintains a critical position in the life sciences landscape, bridging the gap between complex material science and clinical application.
How much funding has Liquidia raised?
Liquidia has raised a total of $233M across 7 funding rounds:
Series A
$6M
Series B
$16M
Series C
$25M
Series D
$25.5M
Debt
$20.5M
Debt
$40M
Debt
$100M
Series A (2006): $6M with participation from Firelake Capital, Siemens, Wakefield Group, and Next47
Series B (2007): $16M led by Firelake Capital, New Enterprise Associates, and Wakefield Group
Series C (2010): $25M supported by Pappas Capital, Firelake Capital, New Enterprise Associates, and Canaan Partners
Series D (2018): $25.5M featuring Morningside Group, New Enterprise Associates, Canaan Partners, and Xeraya Capital
Debt (2021): $20.5M backed by Silicon Valley Bank
Debt (2022): $40M with participation from Silicon Valley Bank
Debt (2025): $100M, investors not publicly disclosed
Key Investors in Liquidia
Firelake Capital
Firelake Strategic Technology Fund is a Palo Alto-based firm that invests in energy, communications, and materials technology, focusing on groundbreaking proprietary solutions for large-scale markets.
New Enterprise Associates
Established in 1977, New Enterprise Associates is a premier venture capital firm headquartered in Menlo Park, dedicated to partnering with entrepreneurs to build transformative businesses.
Canaan Partners
Canaan is an early-stage venture capital firm with a strong focus on healthcare and biopharma, supporting founders from seed through growth stages with extensive expertise in digital health and medical innovation.
What's next for Liquidia?
With the successful closure of this recent financing, Liquidia is poised to enter a critical phase of operational scaling and clinical validation. The strategic deployment of these funds will likely focus on the final stages of regulatory approval and the subsequent commercialization of its lead candidates. As the company transitions from a development-heavy entity to a commercial-stage organization, the focus will shift toward market penetration and the expansion of its therapeutic footprint. Investors and industry analysts will be closely monitoring the firm's ability to translate its particle engineering breakthroughs into sustainable revenue streams, particularly as it navigates the competitive landscape of PAH treatments and pain management solutions.
See full Liquidia company page
